Vyvanse Supply and Quality Issues
ADHD Australia is aware of growing concerns about the availability and quality of Vyvanse
What You Need to Know
Updated July 2025
ADHD Australia is aware of growing concerns about the availability and quality of Vyvanse (lisdexamfetamine dimesilate), a commonly prescribed medication for ADHD. We’re sharing this update to help our community understand what’s going on and what steps to take.
What’s the Issue?
The current Vyvanse shortage is not just about high demand — it also involves quality concerns at an overseas packaging facility.
- Manufacturing Problems: A packaging site in Ireland (Wasdell Europe Limited) received a Statement of Non-Compliance with Good Manufacturing Practice (GMP) from European regulators.
- Batch Destruction: As a result, some batches of Vyvanse were quarantined or destroyed before they reached Australian pharmacies.
- Quality Assurance Gaps: The issue relates to final packaging and quality checks, not the active ingredient, which continues to be manufactured in Germany.
What This Means for You
- Reduced Supply: Fewer Vyvanse capsules are available across multiple strengths (20–70 mg).
- Prescription Challenges: You may find it difficult to fill your script, or your pharmacist may only have limited stock.
- No Change to Safety (if you already have your script): If you have Vyvanse dispensed by an Australian pharmacy, it has passed TGA release standards. There is no evidence of contamination in available products.
What You Can Do
- Talk to your prescriber before making any changes to your medication.
- Don’t ration or split doses without medical advice.
- Ask your pharmacist if they have alternative brands (e.g. dexamphetamine IR) or know when new stock is arriving.
- Check the TGA’s Medicine Shortage Reports Database for real-time updates.
We’re Advocating for You
ADHD Australia is in contact with stakeholders and regulators and will continue advocating for:
- Improved communication and transparency from pharmaceutical companies
- Faster TGA review of substitute or equivalent medications
- A long-term national strategy for ADHD medication security
Stay informed by subscribing to our newsletter or following us on social media. If you’ve been personally affected by this issue and would like to share your story, please get in touch.
This post is for information only and does not constitute medical advice. Please consult your healthcare provider for support tailored to your needs.